Display options
Cite
Rossini F, Pioltelli P, Bolis S, et al. Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes. Clin Drug Investig. 1998;15(5):425-33doi: 10.2165/00044011-199815050-00007.
Rossini, F., Pioltelli, P., Bolis, S., Borin, L., Casaroli, I., Lanzi, E., Maffè, P., Parma, M., Tripputi, P., & Pogliani, E. M. (1998). Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes. Clinical drug investigation, 15(5), 425-33. https://doi.org/10.2165/00044011-199815050-00007
Rossini, F, et al. "Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes." Clinical drug investigation vol. 15,5 (1998): 425-33. doi: https://doi.org/10.2165/00044011-199815050-00007
Rossini F, Pioltelli P, Bolis S, Borin L, Casaroli I, Lanzi E, Maffè P, Parma M, Tripputi P, Pogliani EM. Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes. Clin Drug Investig. 1998;15(5):425-33. doi: 10.2165/00044011-199815050-00007. PMID: 18370498.
Copy Download .nbib Format: NLM
Share it on

Clin Drug Investig. 1998;15(5):425-33. doi: 10.2165/00044011-199815050-00007.

Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes.

Clinical drug investigation

F Rossini, P Pioltelli, S Bolis, L Borin, I Casaroli, E Lanzi, P Maffè, M Parma, P Tripputi, E M Pogliani

Affiliations

  1. Haematology Unit, University of Milan, S. Gerardo Hospital, Monza, Italy.

PMID: 18370498 DOI: 10.2165/00044011-199815050-00007

Abstract

To assess the economic outcomes produced when a conventional antibiotic treatment regimen requiring three administrations per day was replaced with a treatment regimen requiring only one daily administration, the efficacy, tolerability and cost of ceftazidime was compared with that of ceftriaxone (both drugs in combination with amikacin) for the empirical treatment of febrile granulocytopenic patients with haematological malignancy. 102 febrile patient-episodes were randomly assigned to receive ceftazidime (6g in three divided doses) or ceftriaxone (2g as a single daily dose), both in combination with amikacin. The response was evaluable in 94 patients (47 in each group). 75 (80%) patients had an absolute granulocyte count lower than 100/mm(3) at the onset of fever or during the first week of antibiotic therapy. 61 (64.9%) were affected by acute leukaemia. Multiple daily ceftazidime plus amikacin was effective in 33 of 47 (70.2%) patients, and single daily ceftriaxone plus amikacin in 31 of 47 (66%) patients (p > 0.2). Among patients successfully treated, median time to defervescence was 3.3 days (range 1 to 11) for ceftazidime plus amikacin and 4.5 days for ceftriaxone plus amikacin (range 1 to 15) [p = 0.14]; study drugs were continued for 12 (range 7 to 26) and 12.3 days (range 7 to 28), respectively. Our study demonstrated that single daily administration of ceftriaxone was as effective and well tolerated as multiple daily administration of ceftazidime when both were administered in combination with amikacin. Cost analysis showed that compared with the thrice daily regimen, administration of single daily doses of ceftriaxone for a 12-day treatment period would result in a net cost saving of $US392 (626 940 Italian lire).

References

  1. Antimicrob Agents Chemother. 1993 Aug;37(8):1696-700 - PubMed
  2. Chemotherapy. 1992;38(6):420-7 - PubMed
  3. N Engl J Med. 1987 Dec 31;317(27):1692-8 - PubMed
  4. Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S734-40 - PubMed
  5. J Antimicrob Chemother. 1991 May;27 Suppl C:129-39 - PubMed
  6. Ann Intern Med. 1993 Oct 1;119(7 Pt 1):584-93 - PubMed
  7. N Engl J Med. 1993 May 6;328(18):1323-32 - PubMed
  8. Chemotherapy. 1991;37(5):382-8 - PubMed
  9. Haematologica. 1990 Jan-Feb;75(1):69-74 - PubMed
  10. Int J Hematol. 1993 Aug;58(1-2):63-72 - PubMed
  11. J Chemother. 1995 Jun;7 Suppl 2:103-10 - PubMed
  12. Schweiz Med Wochenschr Suppl. 1996;76:21S-27S - PubMed
  13. J Hosp Infect. 1990 Apr;15 Suppl A:41-8 - PubMed
  14. Antimicrob Agents Chemother. 1996 May;40(5):1108-15 - PubMed
  15. Support Care Cancer. 1994 Nov;2(6):347-54 - PubMed
  16. J Antimicrob Chemother. 1991 Apr;27 Suppl B:61-7 - PubMed
  17. Am J Med. 1986 Jul 28;81(1A):11-26 - PubMed
  18. Antimicrob Agents Chemother. 1995 Feb;39(2):445-52 - PubMed
  19. Rev Infect Dis. 1982 Mar-Apr;4(2):294-301 - PubMed
  20. J Infect Dis. 1990 Mar;161(3):397-401 - PubMed
  21. Infection. 1994 Jul-Aug;22(4):271-5 - PubMed

Publication Types